Publications
2022
Boccardi M. Translational process. J Transl Med. 2023;21(1):677. doi: 10.1186/s12967-023-04507-7
Teipel S, Tang Y, Boccardi M. Predicting cognitive decline in older people by structural and molecular imaging. Curr Opin Neurol. 2023;36(4):253-263. doi: 10.1097/WCO.0000000000001172.
Grazia A, Altomare D, Preis L, Monsch AU, Cappa SF, Gauthier S, Frölich L, Winblad B, Welsh-Bohmer KA, Teipel SJ, Boccardi M; Consortium for the Harmonization of Neuropsychological Assessment. Feasibility of a standard cognitive assessment in European academic memory clinics. Alzheimers Dement. 2023;19(6):2276-2286. doi: 10.1002/alz.12830
Dodich A, Boccardi M, Sacco L, Monsch AU, Démonet JF, Filardi M, Logroscino G, Salmon DP, Weinbtraub S, Dubois B, Cappa SF, Cerami C; Consortium for the Harmonization of Neuropsychological Assessment for Neurocognitive Disorders.Alzheimers Dement. Answer to "Social cognition assessment for mild neurocognitive disorders". 2022 Jul;18(7):1441-1442. doi: 10.1002/alz12664. [https://pubmed.ncbi.nlm.nih.gov/35394112/]
Boccardi M, Handels R, Gold M, Grazia A, Lutz MW, Martin M, Nosheny R, Robillard JM, Weidner W, Alexandersson J, Thyrian JR, Winblad B, Barbarino P, Khachaturian AS, Teipel S. Clinical research in dementia: A perspective on implementing innovation. Alzheimers Dement. 2022. doi: 10.1002/alz.12622. [https://pubmed.ncbi.nlm.nih.gov/35325508/]
Boccardi M, Monsch AU, Ferrari C, Altomare D, Berres M, Bos I, Buchmann A, Cerami C, Didic M, Festari C, Nicolosi V, Sacco L, Aerts L, Albanese E, Annoni JM, Ballhausen N, Chicherio C, Démonet JF, Descloux V, Diener S, Ferreira D, Georges J, Gietl A, Girtler N, Kilimann I, Klöppel S, Kustyniuk N, Mecocci P, Mella N, Pigliautile M, Seeher K, Shirk SD, Toraldo A, Brioschi-Guevara A, Chan KCG, Crane PK, Dodich A, Grazia A, Kochan NA, de Oliveira FF, Nobili F, Kukull W, Peters O, Ramakers I, Sachdev PS, Teipel S, Visser PJ, Wagner M, Weintraub S, Westman E, Froelich L, Brodaty H, Dubois B, Cappa SF, Salmon D, Winblad B, Frisoni GB, Kliegel M; Consortium for the Harmonization of Neuropsychological Assessment for Neurocognitive Disorders. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimers Dement. 2022;18(1):29-42. [https://pubmed.ncbi.nlm.nih.gov/33984176/]
Kowe A, Panjaitan H, Klein OA, Boccardi M, Roes M, Teupen S, Teipel S. The impact of participatory dementia research on researchers: A systematic review. Dementia (London). 2022;21(3):1012-1031. [https://pubmed.ncbi.nlm.nih.gov/35152790/]
2021
Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, Bischof GN, Chiotis K, Leuzy A, Wolters EE, Walter MA, Rabinovici GD, Carrillo M, Drzezga A, Hansson O, Nordberg A, Ossenkoppele R, Villemagne VL, Winblad B, Frisoni GB, Garibotto V. The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021;48(7):2070-2085. [https://pubmed.ncbi.nlm.nih.gov/33688996/]
Garibotto V, Boccardi M, Chiti A, Frisoni GB. Molecular imaging and fluid biomarkers of Alzheimer's disease neuropathology: an opportunity for integrated diagnostics. Eur J Nucl Med Mol Imaging. 2021;48(7):2067-2069. [https://pubmed.ncbi.nlm.nih.gov/33688995/]
Cotta Ramusino M, Perini G, Altomare D, Barbarino P, Weidner W, Salvini Porro G, Barkhof F, Rabinovici GD, van der Flier WM, Frisoni GB, Garibotto V, Teipel S, Boccardi M. Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. Eur J Nucl Med Mol Imaging. 2021;48(7):2157-2168.[https://pubmed.ncbi.nlm.nih.gov/33594474/]
Bischof GN, Dodich A, Boccardi M, van Eimeren T, Festari C, Barthel H, Hansson O, Nordberg A, Ossenkoppele R, Sabri O, Giovanni BFG, Garibotto V, Drzezga A. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2110-2120. [https://pubmed.ncbi.nlm.nih.gov/33590274/]
Wolters EE, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O, Nordberg A, Frisoni GB, Garibotto V, Ossenkoppele R. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2097-2109. [https://pubmed.ncbi.nlm.nih.gov/33547556/]
Ashton NJ, Leuzy A, Karikari TK, Mattsson-Carlgren N, Dodich A, Boccardi M, Corre J, Drzezga A, Nordberg A, Ossenkoppele R, Zetterberg H, Blennow K, Frisoni GB, Garibotto V, Hansson O. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging. 2021;48(7):2140-2156. [https://pubmed.ncbi.nlm.nih.gov/33677733/]
Leuzy A, Ashton NJ, Mattsson-Carlgren N, Dodich A, Boccardi M, Corre J, Drzezga A, Nordberg A, Ossenkoppele R, Zetterberg H, Blennow K, Frisoni GB, Garibotto V, Hansson O. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2121-2139. [https://pubmed.ncbi.nlm.nih.gov/33674895/]
Altomare D, Caprioglio C, Assal F, Allali G, Mendes A, Ribaldi F, Ceyzeriat K, Martins M, Tomczyk S, Stampacchia S, Dodich A, Boccardi M, Chicherio C, Frisoni GB, Garibotto V. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. Eur J Nucl Med Mol Imaging. 2021;48(7):2200-2211. [https://pubmed.ncbi.nlm.nih.gov/33638661/]
2020
Boccardi M, Nicolosi V, Festari C, Bianchetti A, Cappa S, Chiasserini D, Falini A, Guerra UP, Nobili F, Padovani A, Sancesario G, Morbelli S, Parnetti L, Tiraboschi P, Muscio C, Perani D, Pizzini FB, Beltramello A, Salvini Porro G, Ciaccio M, Schillaci O, Trabucchi M, Tagliavini F, Frisoni GB. Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. Eur J Neurol. 2020;27(3):475-483. [https://pubmed.ncbi.nlm.nih.gov/31692118/]
Dodich A, Mendes A, Assal F, Chicherio C, Rakotomiaramanana B, Andryszak P, Festari C, Ribaldi F, Scheffler M, Schibli R, Schwarz AJ, Zekry D, Lövblad KO, Boccardi M, Unschuld PG, Gold G, Frisoni GB, Garibotto V. The A/T/N model applied through imaging biomarkers in a memory clinic. Eur J Nucl Med Mol Imaging. 2020;47(2):247-255. [https://pubmed.ncbi.nlm.nih.gov/31792573/]
Ramusino MC, Garibotto V, Bacchin R, Altomare D, Dodich A, Assal F, Mendes A, Costa A, Tinazzi M, Morbelli SD, Bauckneht M, Picco A, Dottorini ME, Tranfaglia C, Farotti L, Salvadori N, Moretti D, Savelli G, Tarallo A, Nobili F, Parapini M, Cavaliere C, Salvatore E, Salvatore M, Boccardi M, Frisoni GB. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2020;47(2):270-280. [https://pubmed.ncbi.nlm.nih.gov/31388720/]
Paghera B, Altomare D, Peli A, Morbelli S, Buschiazzo A, Bauckneht M, Giubbini R, Rodella C, Camoni L, Boccardi M, Festari C, Muscio C, Padovani A, Frisoni GB, Guerra UP. Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability? Q J Nucl Med Mol Imaging. 2020;64(4):414-421. [https://pubmed.ncbi.nlm.nih.gov/31089074/]
2019
Cotta Ramusino M, Altomare D, Bacchin R, Ingala S, Bnà C, Bonetti M, Costa A, Barkhof F, Nicolosi V, Festari C, Frisoni GB, Boccardi M. Medial temporal lobe atrophy and posterior atrophy scales normative values. Neuroimage Clin. 2019;24:101936. [https://pubmed.ncbi.nlm.nih.gov/31382240/]
Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Lopes Alves I, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott JM, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N. AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimers Dement. 2019;15(3):388-399. [https://pubmed.ncbi.nlm.nih.gov/30339801/]
Khlif MS, Werden E, Egorova N, Boccardi M, Redolfi A, Bird L, Brodtmann A. Assessment of longitudinal hippocampal atrophy in the first year after ischemic stroke using automatic segmentation techniques. Neuroimage Clin. 2019;24:102008. [https://pubmed.ncbi.nlm.nih.gov/31711030/]
Olsen RK, Carr VA, Daugherty AM, La Joie R, Amaral RSC, Amunts K, Augustinack JC, Bakker A, Bender AR, Berron D, Boccardi M, Bocchetta M, Burggren AC, Chakravarty MM, Chételat G, de Flores R, DeKraker J, Ding SL, Geerlings MI, Huang Y, Insausti R, Johnson EG, Kanel P, Kedo O, Kennedy KM, Keresztes A, Lee JK, Lindenberger U, Mueller SG, Mulligan EM, Ofen N, Palombo DJ, Pasquini L, Pluta J, Raz N, Rodrigue KM, Schlichting ML, Lee Shing Y, Stark CEL, Steve TA, Suthana NA, Wang L, Werkle-Bergner M, Yushkevich PA, Yu Q, Wisse LEM; Hippocampal Subfields Group. Progress update from the hippocampal subfields group. Alzheimers Dement (Amst). 2019;11:439-449. [https://pubmed.ncbi.nlm.nih.gov/31245529/]
Khlif MS, Egorova N, Werden E, Redolfi A, Boccardi M, DeCarli CS, Fletcher E, Singh B, Li Q, Bird L, Brodtmann A. A comparison of automated segmentation and manual tracing in estimating hippocampal volume in ischemic stroke and healthy control participants. Neuroimage Clin. 2019;21:101581. [https://pubmed.ncbi.nlm.nih.gov/30606656/]
Quattrini G, Pini L, Pievani M, Magni LR, Lanfredi M, Ferrari C, Boccardi M, Bignotti S, Magnaldi S, Cobelli M, Rillosi L, Beneduce R, Rossi G, Frisoni GB, Rossi R. Abnormalities in functional connectivity in borderline personality disorder: Correlations with metacognition and emotion dysregulation. Psychiatry Res Neuroimaging. 2019;283:118-124. [https://pubmed.ncbi.nlm.nih.gov/30591402/]
2018
Altomare D, Ferrari C, Festari C, Guerra UP, Muscio C, Padovani A, Frisoni GB, Boccardi M. Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET. Alzheimers Dement. 2018;14(8):1088-1098. [https://pubmed.ncbi.nlm.nih.gov/29679576/]
Boccardi M, Festari C, Altomare D, Gandolfo F, Orini S, Nobili F, Frisoni GB; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1470-1486. [https://pubmed.ncbi.nlm.nih.gov/29717332/]
Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, Walker Z, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25(10):1201-1217. [https://pubmed.ncbi.nlm.nih.gov/29932266/]
Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, Bouwman F, Drzezga A, Nestor P, Boccardi M, Altomare D, Festari C, Nobili F; EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1534-1545. [https://pubmed.ncbi.nlm.nih.gov/29779045/]
Drzezga A, Altomare D, Festari C, Arbizu J, Orini S, Herholz K, Nestor P, Agosta F, Bouwman F, Nobili F, Walker Z, Frisoni GB, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2018;45(9):1487-1496. [https://pubmed.ncbi.nlm.nih.gov/29756163/]
Bouwman F, Orini S, Gandolfo F, Altomare D, Festari C, Agosta F, Arbizu J, Drzezga A, Nestor P, Nobili F, Walker Z, Morbelli S, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. Eur J Nucl Med Mol Imaging. 2018;45(9):1526-1533. [https://pubmed.ncbi.nlm.nih.gov/29744573/]
Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, Bouwman F, Orini S, Law I, Agosta F, Arbizu J, Boccardi M, Nobili F, Frisoni GB; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1509-1525. [https://pubmed.ncbi.nlm.nih.gov/29736698/]
Nobili F, Festari C, Altomare D, Agosta F, Orini S, Van Laere K, Arbizu J, Bouwman F, Drzezga A, Nestor P, Walker Z, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. Eur J Nucl Med Mol Imaging. 2018;45(9):1557-1566. [https://pubmed.ncbi.nlm.nih.gov/29721650/]
Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, Arbizu J, Bouwman F, Drzezga A, Nestor P, Nobili F, Walker Z, Pagani M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. Eur J Nucl Med Mol Imaging. 2018;45(9):1546-1556. [https://pubmed.ncbi.nlm.nih.gov/29717332/]
Arbizu J, Festari C, Altomare D, Walker Z, Bouwman F, Rivolta J, Orini S, Barthel H, Agosta F, Drzezga A, Nestor P, Boccardi M, Frisoni GB, Nobili F; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging. 2018;45(9):1497-1508. [https://pubmed.ncbi.nlm.nih.gov/29704037/]
Elsiddig AAI, Grosu C, Ferrer Soler C, Scheffler M, Cotta Ramusino M, Trombella S, Gold G, Boccardi M, Frisoni GB. [MRI of medial-temporal atrophy as a biomarker for Alzheimer's disease].Rev Med Suisse. 2018;14(620):1716-1720.[https://pubmed.ncbi.nlm.nih.gov/30255999/]
2017
Boccardi M, Gallo V, Yasui Y, Vineis P, Padovani A, Mosimann U, Giannakopoulos P, Gold G, Dubois B, Jack CR Jr, Winblad B, Frisoni GB, Albanese E; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology. Neurobiol Aging. 2017;52:141-152. [https://pubmed.ncbi.nlm.nih.gov/28317645/]
Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol. 2017; 16 (8): 661-676. [https://pubmed.ncbi.nlm.nih.gov/28721928/]
Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Varrone A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:228-242. [https://pubmed.ncbi.nlm.nih.gov/28317651/]
Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, Garibotto V, Herholz K, Nobili F, Nordberg A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214-227. [https://pubmed.ncbi.nlm.nih.gov/28317650/]
Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, Nobili F, Ratib O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:183-195. [https://pubmed.ncbi.nlm.nih.gov/28317648/]
Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, Frisoni GB, Scheltens P; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:167-182.e1. [https://pubmed.ncbi.nlm.nih.gov/28317647/]
Cerami C, Dubois B, Boccardi M, Monsch AU, Demonet JF, Cappa SF; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:153-166. [https://pubmed.ncbi.nlm.nih.gov/28317646/]
Mattsson N, Lönneborg A, Boccardi M, Blennow K, Hansson O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:196-213. [https://pubmed.ncbi.nlm.nih.gov/28317649/]
Porteri C, Albanese E, Scerri C, Carrillo MC, Snyder HM, Martensson B, Baker M, Giacobini E, Boccardi M, Winblad B, Frisoni GB, Hurst S; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues. Neurobiol Aging. 2017;52:132-140. [https://pubmed.ncbi.nlm.nih.gov/28317644/]
Frisoni GB, Perani D, Bastianello S, Bernardi G, Porteri C, Boccardi M, Cappa SF, Trabucchi M, Padovani A. Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. Neurobiol Aging. 2017;52:119-131. [https://pubmed.ncbi.nlm.nih.gov/28317643/]
Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, Ferrari C, Guerra UP, Paghera B, Muscio C, Bianchetti A, Volta GD, Turla M, Cotelli MS, Gennuso M, Prelle A, Zanetti O, Lussignoli G, Mirabile D, Bellandi D, Gentile S, Belotti G, Villani D, Harach T, Bolmont T, Padovani A, Boccardi M, Frisoni GB; INDIA-FBP Group. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60-68. [https://pubmed.ncbi.nlm.nih.gov/27776263/]
Wolf D, Bocchetta M, Preboske GM, Boccardi M, Grothe MJ; Alzheimer's Disease Neuroimaging Initiative. Reference standard space hippocampus labels according to the European Alzheimer's Disease Consortium-Alzheimer's Disease Neuroimaging Initiative harmonized protocol: Utility in automated volumetry. Alzheimers Dement. 2017;13(8):893-902. [https://pubmed.ncbi.nlm.nih.gov/28238738/]
Wisse LEM, Daugherty AM, Olsen RK, Berron D, Carr VA, Stark CEL, Amaral RSC, Amunts K, Augustinack JC, Bender AR, Bernstein JD, Boccardi M, Bocchetta M, Burggren A, Chakravarty MM, Chupin M, Ekstrom A, de Flores R, Insausti R, Kanel P, Kedo O, Kennedy KM, Kerchner GA, LaRocque KF, Liu X, Maass A, Malykhin N, Mueller SG, Ofen N, Palombo DJ, Parekh MB, Pluta JB, Pruessner JC, Raz N, Rodrigue KM, Schoemaker D, Shafer AT, Steve TA, Suthana N, Wang L, Winterburn JL, Yassa MA, Yushkevich PA, la Joie R; Hippocampal Subfields Group. A harmonized segmentation protocol for hippocampal and parahippocampal subregions: Why do we need one and what are the key goals? Hippocampus. 2017;27(1):3-11. [https://pubmed.ncbi.nlm.nih.gov/27862600/]
2016
Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, Pizzocaro C, Lussignoli G, Geroldi C, Zanetti O, Cotelli MS, Turla M, Borroni B, Rozzini L, Mirabile D, Defanti C, Gennuso M, Prelle A, Gentile S, Morandi A, Vollaro S, Volta GD, Bianchetti A, Conti MZ, Cappuccio M, Carbone P, Bellandi D, Abruzzi L, Bettoni L, Villani D, Raimondi MC, Lanari A, Ciccone A, Facchi E, Di Fazio I, Rozzini R, Boffelli S, Manzoni L, Salvi GP, Cavaliere S, Belotti G, Avanzi S, Pasqualetti P, Muscio C, Padovani A, Frisoni GB; Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. JAMA Neurol. 2016 1;73(12):1417-1424. [https://pubmed.ncbi.nlm.nih.gov/27802513/]
Maglietta R, Amoroso N, Boccardi M, Bruno S, Chincarini A, Frisoni GB, Inglese P, Redolfi A, Tangaro S, Tateo A, Bellotti R; Alzheimers Disease Neuroimaging Initiative. Automated hippocampal segmentation in 3D MRI using random undersampling with boosting algorithm. Pattern Anal Appl. 2016;19:579-591.[https://pubmed.ncbi.nlm.nih.gov/27110218/]
Frisoni GB, Boccardi M. MRI for Pre-Dementia Trials. J Prev Alzheimers Dis. 2016;3(1):5-7. [https://pubmed.ncbi.nlm.nih.gov/29214276/]
Boccardi M, Altomare D, Ferrari C, Festari C, Antelmi L, Pievani M, Tarallo A, Muscio C, Guerra UP, Paghera B, Padovani A, Frisoni GB; INDIA-FBP Working Group. Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic.Neurodegener Dis. 2016;16(1-2):111-7. [https://pubmed.ncbi.nlm.nih.gov/26618706/]
Chincarini A, Sensi F, Rei L, Gemme G, Squarcia S, Longo R, Brun F, Tangaro S, Bellotti R, Amoroso N, Bocchetta M, Redolfi A, Bosco P, Boccardi M, Frisoni GB, Nobili F; Alzheimer's Disease Neuroimaging Initiative. Integrating longitudinal information in hippocampal volume measurements for the early detection of Alzheimer's disease.Neuroimage. 2016;125:834-847. [https://pubmed.ncbi.nlm.nih.gov/26515904/]
2015
Boccardi M, Bocchetta M, Ganzola R, Robitaille N, Redolfi A, Duchesne S, Jack CR Jr, Frisoni GB; EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging Initiative. Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation. Alzheimers Dement. 2015;11(2):184-94. [https://pubmed.ncbi.nlm.nih.gov/23706515/]
Boccardi M, Bocchetta M, Apostolova LG, Barnes J, Bartzokis G, Corbetta G, DeCarli C, deToledo-Morrell L, Firbank M, Ganzola R, Gerritsen L, Henneman W, Killiany RJ, Malykhin N, Pasqualetti P, Pruessner JC, Redolfi A, Robitaille N, Soininen H, Tolomeo D, Wang L, Watson C, Wolf H, Duvernoy H, Duchesne S, Jack CR Jr, Frisoni GB; EADC-ADNI Working Group on the Harmonized Protocol for Manual Hippocampal Segmentation. Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimers Dement. 2015;11(2):126-38. [https://pubmed.ncbi.nlm.nih.gov/25130658/]
Frisoni GB, Jack CR Jr, Bocchetta M, Bauer C, Frederiksen KS, Liu Y, Preboske G, Swihart T, Blair M, Cavedo E, Grothe MJ, Lanfredi M, Martinez O, Nishikawa M, Portegies M, Stoub T, Ward C, Apostolova LG, Ganzola R, Wolf D, Barkhof F, Bartzokis G, DeCarli C, Csernansky JG, deToledo-Morrell L, Geerlings MI, Kaye J, Killiany RJ, Lehéricy S, Matsuda H, O'Brien J, Silbert LC, Scheltens P, Soininen H, Teipel S, Waldemar G, Fellgiebel A, Barnes J, Firbank M, Gerritsen L, Henneman W, Malykhin N, Pruessner JC, Wang L, Watson C, Wolf H, deLeon M, Pantel J, Ferrari C, Bosco P, Pasqualetti P, Duchesne S, Duvernoy H, Boccardi M; EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging Initiative. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement. 2015;11(2):111-25. [https://pubmed.ncbi.nlm.nih.gov/25267715/]
Bocchetta M, Boccardi M, Ganzola R, Apostolova LG, Preboske G, Wolf D, Ferrari C, Pasqualetti P, Robitaille N, Duchesne S, Jack CR Jr, Frisoni GB; EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging Initiative. Harmonized benchmark labels of the hippocampus on magnetic resonance: the EADC-ADNI project. Alzheimers Dement. 2015;11(2):151-60.e5. [https://pubmed.ncbi.nlm.nih.gov/25223727/]
Duchesne S, Valdivia F, Robitaille N, Mouiha A, Valdivia FA, Bocchetta M, Apostolova LG, Ganzola R, Preboske G, Wolf D, Boccardi M, Jack CR Jr, Frisoni GB; EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging Initiative. Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. Alzheimers Dement. 2015;11(2):161-74. [https://pubmed.ncbi.nlm.nih.gov/25617509/]
Boccardi M, Bocchetta M, Morency FC, Collins DL, Nishikawa M, Ganzola R, Grothe MJ, Wolf D, Redolfi A, Pievani M, Antelmi L, Fellgiebel A, Matsuda H, Teipel S, Duchesne S, Jack CR Jr, Frisoni GB; EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging Initiative. Training labels for hippocampal segmentation based on the EADC-ADNI harmonized hippocampal protocol. Alzheimers Dement. 2015;11(2):175-83. [https://pubmed.ncbi.nlm.nih.gov/25616957/]
Apostolova LG, Zarow C, Biado K, Hurtz S, Boccardi M, Somme J, Honarpisheh H, Blanken AE, Brook J, Tung S, Lo D, Ng D, Alger JR, Vinters HV, Bocchetta M, Duvernoy H, Jack CR Jr, Frisoni GB; EADC-ADNI Working Group on the Harmonized Protocol for Manual Hippocampal Segmentation. Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. Alzheimers Dement. 2015;11(2):139-50. [https://pubmed.ncbi.nlm.nih.gov/25620800/]
Inglese P, Amoroso N, Boccardi M, Bocchetta M, Bruno S, Chincarini A, Errico R, Frisoni GB, Maglietta R, Redolfi A, Sensi F, Tangaro S, Tateo A, Bellotti R; Alzheimer's Disease Neuroimaging Initiative. Multiple RF classifier for the hippocampus segmentation: Method and validation on EADC-ADNI Harmonized Hippocampal Protocol. Phys Med. 2015;31(8):1085-1091. [https://pubmed.ncbi.nlm.nih.gov/26481815/]
Yushkevich PA, Amaral RS, Augustinack JC, Bender AR, Bernstein JD, Boccardi M, Bocchetta M, Burggren AC, Carr VA, Chakravarty MM, Chételat G, Daugherty AM, Davachi L, Ding SL, Ekstrom A, Geerlings MI, Hassan A, Huang Y, Iglesias JE, La Joie R, Kerchner GA, LaRocque KF, Libby LA, Malykhin N, Mueller SG, Olsen RK, Palombo DJ, Parekh MB, Pluta JB, Preston AR, Pruessner JC, Ranganath C, Raz N, Schlichting ML, Schoemaker D, Singh S, Stark CE, Suthana N, Tompary A, Turowski MM, Van Leemput K, Wagner AD, Wang L, Winterburn JL, Wisse LE, Yassa MA, Zeineh MM; Hippocampal Subfields Group (HSG). Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: towards a harmonized segmentation protocol. Neuroimage. 2015;111:526-41. [https://pubmed.ncbi.nlm.nih.gov/25596463/]
Rossi R, Lanfredi M, Pievani M, Boccardi M, Rasser PE, Thompson PM, Cavedo E, Cotelli M, Rosini S, Beneduce R, Bignotti S, Magni LR, Rillosi L, Magnaldi S, Cobelli M, Rossi G, Frisoni GB. Abnormalities in cortical gray matter density in borderline personality disorder. Eur Psychiatry. 2015;30(2):221-7. [https://pubmed.ncbi.nlm.nih.gov/25561291/]
Babiloni C, Del Percio C, Boccardi M, Lizio R, Lopez S, Carducci F, Marzano N, Soricelli A, Ferri R, Triggiani AI, Prestia A, Salinari S, Rasser PE, Basar E, Famà F, Nobili F, Yener G, Emek-Savaş DD, Gesualdo L, Mundi C, Thompson PM, Rossini PM, Frisoni GB. Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2015;36(2):556-70. [https://pubmed.ncbi.nlm.nih.gov/25442118/]
Prestia A, Cavedo E, Boccardi M, Muscio C, Adorni A, Geroldi C, Bonetti M, Thompson PM, Frisoni GB. Hippocampal and amygdalar local structural differences in elderly patients with schizophrenia. Am J Geriatr Psychiatry. 2015;23(1):47-58. [https://pubmed.ncbi.nlm.nih.gov/24534522/]
2014
Boccardi M, Bocchetta M, Apostolova LG, Preboske G, Robitaille N, Pasqualetti P, Collins LD, Duchesne S, Jack CR Jr, Frisoni GB; EADC-ADNI Working Group on The Harmonized Protocol for Hippocampal Volumetry; Alzheimer's Disease Neuroimaging Initiative. Establishing magnetic resonance images orientation for the EADC-ADNI manual hippocampal segmentation protocol. J Neuroimaging. 2014;24(5):509-14.[ https://pubmed.ncbi.nlm.nih.gov/24279479/]
Hill DLG, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, Boccardi M, Brewer J, Brumfield M, Cantillon M, Cole PE, Fox N, Frisoni GB, Jack C, Kelleher T, Luo F, Novak G, Maguire P, Meibach R, Patterson P, Bain L, Sampaio C, Raunig D, Soares H, Suhy J, Wang H, Wolz R, Stephenson D. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimers Dement. 2014;10(4):421-429.e3. [https://pubmed.ncbi.nlm.nih.gov/24985687/]
Tangaro S, Amoroso N, Boccardi M, Bruno S, Chincarini A, Ferraro G, Frisoni GB, Maglietta R, Redolfi A, Rei L, Tateo A, Bellotti R; Alzheimers Disease Neuroimaging Initiative. Automated voxel-by-voxel tissue classification for hippocampal segmentation: methods and validation. Phys Med. 2014;30(8):878-87. [https://pubmed.ncbi.nlm.nih.gov/25018049/]
Preti A, Muscio C, Boccardi M, Lorenzi M, de Girolamo G, Frisoni G. Impact of alcohol consumption in healthy adults: a magnetic resonance imaging investigation. Psychiatry Res. 2014;224(2):96-103. [https://pubmed.ncbi.nlm.nih.gov/25172407/]
Cavedo E, Pievani M, Boccardi M, Galluzzi S, Bocchetta M, Bonetti M, Thompson PM, Frisoni GB. Medial temporal atrophy in early and late-onset Alzheimer's disease. Neurobiol Aging. 2014;35(9):2004-12. [https://pubmed.ncbi.nlm.nih.gov/24721821/]
2013
Boccardi M, Bocchetta M, Aronen HJ, Repo-Tiihonen E, Vaurio O, Thompson PM, Tiihonen J, Frisoni GB. Atypical nucleus accumbens morphology in psychopathy: another limbic piece in the puzzle. Int J Law Psychiatry. 2013;36(2):157-67. [https://pubmed.ncbi.nlm.nih.gov/23399314/]
Pievani M, Bocchetta M, Boccardi M, Cavedo E, Bonetti M, Thompson PM, Frisoni GB. Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study. Neurobiol Aging. 2013;34(7):1728-39. [https://pubmed.ncbi.nlm.nih.gov/23428181/]
Rossi R, Pievani M, Lorenzi M, Boccardi M, Beneduce R, Bignotti S, Borsci G, Cotelli M, Giannakopoulos P, Magni LR, Rillosi L, Rosini S, Rossi G, Frisoni GB. Structural brain features of borderline personality and bipolar disorders. Psychiatry Res. 2013;213(2):83-91. [https://pubmed.ncbi.nlm.nih.gov/23146251/]
2012
Rossi R, Lanfredi M, Pievani M, Boccardi M, Beneduce R, Rillosi L, Giannakopoulos P, Thompson PM, Rossi G, Frisoni GB. Volumetric and topographic differences in hippocampal subdivisions in borderline personality and bipolar disorders. Psychiatry Res. 2012;203(2-3):132-8. [https://pubmed.ncbi.nlm.nih.gov/22944368/]
Cavedo E, Galluzzi S, Pievani M, Boccardi M, Frisoni GB. Norms for imaging markers of brain reserve. J Alzheimers Dis. 2012;31(3):623-33. [https://pubmed.ncbi.nlm.nih.gov/22672878/]
2011
Boccardi M, Ganzola R, Bocchetta M, Pievani M, Redolfi A, Bartzokis G, Camicioli R, Csernansky JG, de Leon MJ, deToledo-Morrell L, Killiany RJ, Lehéricy S, Pantel J, Pruessner JC, Soininen H, Watson C, Duchesne S, Jack CR Jr, Frisoni GB. Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol. J Alzheimers Dis. 2011;26 Suppl 3(0 3):61-75. [https://pubmed.ncbi.nlm.nih.gov/21971451/]
Boccardi M, Frisoni GB, Hare RD, Cavedo E, Najt P, Pievani M, Rasser PE, Laakso MP, Aronen HJ, Repo-Tiihonen E, Vaurio O, Thompson PM, Tiihonen J. Cortex and amygdala morphology in psychopathy. Psychiatry Res. 2011;193(2):85-92. [https://pubmed.ncbi.nlm.nih.gov/21676597/]
Prestia A, Boccardi M, Galluzzi S, Cavedo E, Adorni A, Soricelli A, Bonetti M, Geroldi C, Giannakopoulos P, Thompson P, Frisoni G. Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. Psychiatry Res. 2011;192(2):77-83. [https://pubmed.ncbi.nlm.nih.gov/21458960/]
Cavedo E, Boccardi M, Ganzola R, Canu E, Beltramello A, Caltagirone C, Thompson PM, Frisoni GB. Local amygdala structural differences with 3T MRI in patients with Alzheimer disease. Neurology. 2011;76(8):727-33. [https://pubmed.ncbi.nlm.nih.gov/21339500/]
2010
Boccardi M, Ganzola R, Rossi R, Sabattoli F, Laakso MP, Repo-Tiihonen E, Vaurio O, Könönen M, Aronen HJ, Thompson PM, Frisoni GB, Tiihonen J. Abnormal hippocampal shape in offenders with psychopathy. Hum Brain Mapp. 2010;31(3):438-47. [https://pubmed.ncbi.nlm.nih.gov/19718651/]
Boccardi M, Almici M, Bresciani L, Caroli A, Bonetti M, Monchieri S, Gennarelli M, Frisoni GB. Clinical and medial temporal features in a family with mood disorders. Neurosci Lett. 2010;468(2):93-7. [https://pubmed.ncbi.nlm.nih.gov/19874870/]
Benussi L, Ghidoni R, Galimberti D, Boccardi M, Fenoglio C, Scarpini E, Frisoni GB, Binetti G. The CST3 B haplotype is associated with frontotemporal lobar degeneration. Eur J Neurol. 2010;17(1):143-6. [https://pubmed.ncbi.nlm.nih.gov/19674067/]
2009
Galluzzi S, Testa C, Boccardi M, Bresciani L, Benussi L, Ghidoni R, Beltramello A, Bonetti M, Bono G, Falini A, Magnani G, Minonzio G, Piovan E, Binetti G, Frisoni GB. The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clin Exp Res. 2009;21(4-5):266-76.[https://pubmed.ncbi.nlm.nih.gov/19959914/]
Babiloni C, Pievani M, Vecchio F, Geroldi C, Eusebi F, Fracassi C, Fletcher E, De Carli C, Boccardi M, Rossini PM, Frisoni GB. White-matter lesions along the cholinergic tracts are related to cortical sources of EEG rhythms in amnesic mild cognitive impairment. Hum Brain Mapp. 2009;30(5):1431-43. [https://pubmed.ncbi.nlm.nih.gov/19097164/]
Canu E, Boccardi M, Ghidoni R, Benussi L, Duchesne S, Testa C, Binetti G, Frisoni GB. HOXA1 A218G polymorphism is associated with smaller cerebellar volume in healthy humans. J Neuroimaging. 2009;19(4):353-8. [https://pubmed.ncbi.nlm.nih.gov/19018953/]
Canu E, Boccardi M, Ghidoni R, Benussi L, Testa C, Pievani M, Bonetti M, Binetti G, Frisoni GB. H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers. Eur J Hum Genet. 2009;17(3):287-94. [https://pubmed.ncbi.nlm.nih.gov/18854867/]
Borsci G, Boccardi M, Rossi R, Rossi G, Perez J, Bonetti M, Frisoni GB. Alexithymia in healthy women: a brain morphology study. J Affect Disord. 2009;114(1-3):208-15. [https://pubmed.ncbi.nlm.nih.gov/18718670/]
2008
Sabattoli F, Boccardi M, Galluzzi S, Treves A, Thompson PM, Frisoni GB. Hippocampal shape differences in dementia with Lewy bodies. Neuroimage. 2008;41(3):699-705. [https://pubmed.ncbi.nlm.nih.gov/18467130/]
Boccardi M, Scassellati C, Ghidoni R, Testa C, Benussi L, Bonetti M, Bocchio-Chiavetto L, Gennarelli M, Binetti G, Frisoni GB. Effect of the XbaI polymorphism of estrogen receptor alpha on postmenopausal gray matter. Neurosci Lett. 2008;434(3):304-9. [https://pubmed.ncbi.nlm.nih.gov/18342444/]
2006
Boccardi M, Frisoni GB. Cognitive rehabilitation for severe dementia: critical observations for better use of existing knowledge. Mech Ageing Dev. 2006;127(2):166-72. [https://pubmed.ncbi.nlm.nih.gov/16280151/]
Boccardi M, Ghidoni R, Govoni S, Testa C, Benussi L, Bonetti M, Binetti G, Frisoni GB. Effects of hormone therapy on brain morphology of healthy postmenopausal women: a Voxel-based morphometry study. Menopause. 2006;13(4):584-91. [https://pubmed.ncbi.nlm.nih.gov/16837880/]
Pennanen C, Testa C, Boccardi M, Laakso MP, Hallikainen M, Helkala EL, Hänninen T, Kivipelto M, Könönen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H. The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: a voxel-based morphometric study. Dement Geriatr Cogn Disord. 2006;22(1):60-6. [https://pubmed.ncbi.nlm.nih.gov/16682795/]
Rossi R, Boccardi M, Sabattoli F, Galluzzi S, Alaimo G, Testa C, Frisoni GB. Topographic correspondence between white matter hyperintensities and brain atrophy. J Neurol. 2006;253(7):919-27. [https://pubmed.ncbi.nlm.nih.gov/16502217/]
Filippini N, Scassellati C, Boccardi M, Pievani M, Testa C, Bocchio-Chiavetto L, Frisoni GB, Gennarelli M. Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. Eur J Hum Genet. 2006;14(4):443-9. [https://pubmed.ncbi.nlm.nih.gov/16434999/]
Ghidoni R, Boccardi M, Benussi L, Testa C, Villa A, Pievani M, Gigola L, Sabattoli F, Barbiero L, Frisoni GB, Binetti G. Effects of estrogens on cognition and brain morphology: involvement of the cerebellum. Maturitas. 2006;54(3):222-8. [https://pubmed.ncbi.nlm.nih.gov/16343828/]
2005 and before
Boccardi M, Sabattoli F, Laakso MP, Testa C, Rossi R, Beltramello A, Soininen H, Frisoni GB. Frontotemporal dementia as a neural system disease. Neurobiol Aging. 2005 Jan;26(1):37-44. [https://pubmed.ncbi.nlm.nih.gov/15585344/]
Boccardi M, Sabattoli F, Testa C, Beltramello A, Soininen H, Frisoni GB. APOE and modulation of Alzheimer's and frontotemporal dementia. Neurosci Lett. 2004;356(3):167-70. [https://pubmed.ncbi.nlm.nih.gov/15036621/
Boccardi M, Laakso MP, Bresciani L, Galluzzi S, Geroldi C, Beltramello A, Soininen H, Frisoni GB. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiol Aging. 2003;24(1):95-103. [https://pubmed.ncbi.nlm.nih.gov/12493555/]
Boccardi M, Pennanen C, Laakso MP, Testa C, Geroldi C, Soininen H, Frisoni GB. Amygdaloid atrophy in frontotemporal dementia and Alzheimer's disease. Neurosci Lett. 2002;335(2):139-43. [https://pubmed.ncbi.nlm.nih.gov/12459517/]
Boccardi M, Laakso MP, Bresciani L, Geroldi C, Beltramello A, Frisoni GB. Clinical characteristics of frontotemporal patients with symmetric brain atrophy. Eur Arch Psychiatry Clin Neurosci. 2002;252(5):235-9. [https://pubmed.ncbi.nlm.nih.gov/12451466/]